UNSPSC 85819432: Transfusion of nonautologous serum albumin into peripheral vein, open approach

This classification denotes the group of activities that yields a surgical intervention or procedure to transfusion of nonautologous serum albumin into peripheral vein, open approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 30230J1

UNSPSC 85819432 Transfusion of nonautologous serum albumin into peripheral vein, open approach is a Commodity code that shows little relevant recent state and local procurement activity. The recent opportunities posted under this code do not involve serum albumin transfusion or any blood-product administration. Instead, the opportunities reflect a broader mismatch between the code's nominal clinical scope and what state and local issuing bodies are actually buying: independent medical evaluation services for disability benefit determinations, surgical and medical procedure carve-out benefit programs, occupational medical surveillance, emergency and specialty medical services for detained youth, pharmacy benefit management, and temporary health professional staffing. These opportunities span administrative, occupational health, and staffing domains rather than the specific transfusion therapy the code nominally describes.

The issuing bodies include a city retirement office (City of Phoenix), municipal governments (City of Long Beach, Collier County, Harris County), a state transportation department (Washington State Department of Transportation), and a county health system (County of Santa Clara). Geographic activity appears across Arizona, California, Florida, Texas, and Washington, though the opportunities listed do not cluster around any single state or region. The Phoenix and Long Beach solicitations closed or are closing in October 2026; the Washington State Ferries occupational medical surveillance RFP closes October 9, 2026 with a pre-bid conference on August 31, 2026. Given the persistent mismatch between the code's clinical definition and the actual scope of posted opportunities, this code does not offer a reliable signal for business development professionals targeting state and local transfusion-therapy procurement.